Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Associated Therapies: -

Clinical Trials

Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

First Posted Date: 2005-01-31

Last Posted Date: 2006-08-04

Lead Sponsor: AGO Study Group

Target Recruit Count: 900

Registration Number: NCT00102375

Locations: 🇩🇪
University Clinic Carl Gustav Carus, Gynecological hospital, Dresden, Germany
🇩🇪
Gynecologic Hospital of the Medical Facilities RWTH, Aachen, Germany
🇩🇪
University Gynecologic Hospital Grosshadern, Muenchen, Germany

and more 12 locations

Use of Topotecan in Patients With Refractory Acute Leukemia

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma
Leukemia

Interventions: Drug: Topotecan
Drug: Mitozantrone
Drug: Etoposide

First Posted Date: 2004-12-31

Last Posted Date: 2013-09-25

Lead Sponsor: US Department of Veterans Affairs

Target Recruit Count: 10

Registration Number: NCT00100477

Locations: 🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Plasma Cell Neoplasm
Multiple Myeloma

Interventions: Drug: etoposide phosphate
Drug: melphalan
Drug: topotecan
Procedure: Autologous Stem Cell Rescue

First Posted Date: 2004-02-02

Last Posted Date: 2019-11-08

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 131

Registration Number: NCT00005792

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Phase 2

Completed

Conditions: Peritoneal Cancer
Ovarian Cancer
Neoplasms, Ovarian
Fallopian Tube Cancer

First Posted Date: 2003-05-28

Last Posted Date: 2017-06-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 75

Registration Number: NCT00061308

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Drug: Topotecan

First Posted Date: 2003-05-07

Last Posted Date: 2012-09-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 41

Registration Number: NCT00005793

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Biological: G-CSF
Drug: Cisplatin
Drug: Irinotecan
Drug: Etoposide
Drug: Topotecan

First Posted Date: 2003-04-09

Last Posted Date: 2023-07-05

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 140

Registration Number: NCT00057837

Locations: 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States
🇺🇸
St. Luke's Regional Medical Center, Sioux City, Iowa, United States

and more 75 locations

Phase I Study of Intrathecal Topotecan

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Meningeal Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00001333

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small-Cell Lung Cancer

First Posted Date: 2002-11-20

Last Posted Date: 2013-03-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 760

Registration Number: NCT00049998

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Lung Cancer, Small Cell
Solid Tumor Cancer

Interventions: Drug: topotecan

First Posted Date: 2002-09-23

Last Posted Date: 2017-05-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT00046111

Locations: 🇨🇦
GSK Investigational Site, Ottawa, Ontario, Canada

The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)

Phase 2

Completed

Conditions: Small Cell Lung Cancer
Lung Cancer, Small Cell

First Posted Date: 2002-08-15

Last Posted Date: 2017-05-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT00043862

Locations: 🇺🇸
GSK Investigational Site, Wausau, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy